CCL18 — Potential Biomarker of Fibroinflammatory Activity in Chronic Periaortitis

Kollert, Florian; Binder, Moritz; Probst, Corina; Uhl, Markus; Zirlik, Andreas; Kayser, Gian; Voll, Reinhard; Peter, Hans‐Hartmut; Zissel, Gernot; Prasse, Antje; Warnatz, Klaus

doi:10.3899/jrheum.111143

Cited by 13 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, enhanced CCL18 production has been demonstrated in several human diseases, including various malignancies and inflammatory joint, lung, skin, and vessel diseases (). A recent study also showed that serum CCL18 concentrations reflected fibroinflammatory activity and extent of disease in patients with chronic periaortitis ().…”

Section: Discussionmentioning

confidence: 96%

DNA Microarray Analysis of Labial Salivary Glands in IgG4‐Related Disease: Comparison With Sjögren's Syndrome

Tsuboi

Nakai

Iizuka

et al. 2014

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective. To compare gene expression in labial salivary glands (LSGs) from patients with IgG4-related disease with that in LSGs from patients with Sjögren's syndrome (SS).Methods. Gene expression was analyzed by DNA microarray in LSG samples from 5 patients with IgG4-related disease, 5 SS patients, and 3 healthy controls. Genes differentially expressed in IgG4-related disease and SS were identified, and gene annotation enrichment analysis of these differentially expressed genes was performed using Gene Ontology (GO) annotation. Validation of the results was performed by quantitative polymerase chain reaction (PCR) using LSG samples from 9 patients with IgG4-related disease, 10 SS patients, and 4 controls.Results. Gene expression patterns in patients with IgG4-related disease, SS patients, and healthy controls were quite different from each other in hierarchical clustering as well as in principal components analysis. In IgG4-related disease compared with SS, a total of 1,771 probe sets (corresponding to 1,321 genes) were identified as up-regulated, and 1,785 probe sets (corresponding to 1,320 genes) were identified as downregulated (false discovery rate of <5%). GO term analysis indicated that the up-regulated set of differentially expressed genes in IgG4-related disease encoded proteins that function in cell proliferation, extracellular matrix organization, and organ development. PCR validated significantly higher expression of lactotransferrin in patients with IgG4-related disease than in SS patients (P < 0.05) and significantly higher expression of CCL18 in patients with IgG4-related disease than in SS patients and controls (P < 0.05).Conclusion. The results clearly showed that the gene expression pattern in LSGs from patients with IgG4-related disease is different from that in LSGs from SS patients.

show abstract

Section: Discussionmentioning

confidence: 96%

DNA Microarray Analysis of Labial Salivary Glands in IgG4‐Related Disease: Comparison With Sjögren's Syndrome

Tsuboi

Nakai

Iizuka

et al. 2014

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

“…We analyzed the release of key inflammatory cytokines at days 1, 3 and 6 of incubation by ELISA and the expression of key surface markers by immunofluorescence and confocal microscopy. As key inflammatory cytokines we took TNF-α (marker of M1 response) and CCL18 (marker of M2 response) which are shown to take part in chronic inflammation [102,103]. For the study of surface markers, we analyzed the expression of CD206 (marker of M2 response, strongly up-regulated in macrophages during chronic inflammation [104]) and stabilin-1 (marker of M2 response with tolerogenic functions [38]).…”

Section: Application Of Ex Vivo Monocyte-based Test Systemmentioning

confidence: 99%

Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic Inflammation

Kzhyshkowska¹,

Gudima

Moganti

et al. 2016

Transfus Med Hemother

View full text Add to dashboard Cite

Low-grade chronic inflammation underlies the development of the most dangerous cardiometabolic disorders including type 2 diabetes and its vascular complications. In contrast to acute inflammation induced by bacteria and viruses, chronic inflammation can be driven by abnormal reaction to endogenous factors, including Th2 cytokines, metabolic factors like advanced glycation end products (AGEs), modified lipoproteins, or hyperglycemia. The key innate immune cells that recognize these factors in blood circulation are monocytes. Inflammatory programming of monocytes which migrate into tissues can, in turn, result into generation of tissue macrophages with pathological functions. Therefore, determination of the molecular and functional phenotype of circulating monocytes is a very promising diagnostic tool for the identification of hidden inflammation, which can precede the development of the pathology. Here we propose a new test system for the identification of inflammatory programming of monocytes: surface biomarkers and ex vivo functional system. We summarize the current knowledge about surface biomarkers for monocyte subsets, including CD16, CCR2, CX3CR1, CD64, stabilin-1 and CD36, and their association with inflammatory human disorders. Furthermore, we present the design of an ex vivo monocyte-based test system with minimal set of parameters as a potential diagnostic tool for the identification of personalized inflammatory responses.

show abstract

“…CCL18 is mainly expressed and spontaneously secreted by cancer cells and stoma cells including monocytes, macrophages and immature dendritic cells etc. CCL18 secreted from M2-type TAMs is increased not only in chronic inflammations 24, fibrotic diseases 25, 26 and white adipose tissue dysfunction 27, but also in various types of neoplastic diseases. Song's team determined that serum CCL18 was obviously elevated in patients with breast carcinoma, and high CCL18 in the serum was linked with lymph node metastasis and worse histopathological typing, which was an independent influencing factor in the prognosis of patients with breast cancer 12.…”

Section: Discussionmentioning

confidence: 99%

High serum CCL18 predicts a poor prognosis in patients with laryngeal squamous cell carcinoma

et al. 2019

View full text Add to dashboard Cite

CCL18 is a cytokine secreted by M2 type tumor associated macrophages, which frequently over-expressed in diverse human cancers. However, the clinical significance of serum CCL18 in patients with laryngeal squamous cell carcinoma (LSCC) remains unknown. In this study, serum CCL18 was initially quantified by enzyme-linked immunosorbent assay (ELISA) in 146 patients with LSCC, 25 patients with precancerous lesions and 72 healthy volunteers. In addition, the correlations between serum CCL18 and clinicopathological parameters were analyzed. Our data revealed that serum CCL18 was obviously increased in patients with LSCC. Moreover, serum CCL18 level was significantly associated with primary tumor site (Glottic vs Others), T classification (T1+T2 vs T3+T4), clinical stage (I+II vs III+IV) and lymph node metastasis (N0 vs N+). Survival analysis demonstrated that patients with high serum CCL18 displayed a shorter survival time than those in patients with low serum CCL18. Importantly, serum CCL18 level and clinical stage were independent prognostic factors in patients with LSCC. Taken together, serum CCL18 could be used as a promising biomarker in patients with LSCC.

show abstract

CCL18 — Potential Biomarker of Fibroinflammatory Activity in Chronic Periaortitis

Abstract: Serum concentration of CCL18 reflects fibroinflammatory activity and extent of disease in patients with chronic periaortitis.

Cited by 13 publications

References 34 publications

DNA Microarray Analysis of Labial Salivary Glands in IgG4‐Related Disease: Comparison With Sjögren's Syndrome

DNA Microarray Analysis of Labial Salivary Glands in IgG4‐Related Disease: Comparison With Sjögren's Syndrome

Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic Inflammation

High serum CCL18 predicts a poor prognosis in patients with laryngeal squamous cell carcinoma

Contact Info

Product

Resources

About